Pharmaceutical Payments to Japanese Certificated Hematologists: A Retrospective Analysis of Personal Payments from Pharmaceutical Companies between 2016 and 2019
Eiji Kusumi, View ORCID ProfileAnju Murayama, Sae Kamamoto, Moe Kawashima, Makoto Yoshida, Hiroaki Saito, Toyoaki Sawano, Erika Yamashita, Tetsuya Tanimoto, Akihiko Ozaki
doi: https://doi.org/10.1101/2022.01.17.22269284
Eiji Kusumi
1Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku-ku, Tokyo, Japan
MDAnju Murayama
2Medical Governance Research Institute, Minato-ku, Tokyo, Japan
3Tohoku University School of Medicine, Sendai City, Miyagi, Japan
Sae Kamamoto
2Medical Governance Research Institute, Minato-ku, Tokyo, Japan
4Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Moe Kawashima
2Medical Governance Research Institute, Minato-ku, Tokyo, Japan
5Fukushima Medical University, Fukushima city, Fukushima, Japan
Makoto Yoshida
2Medical Governance Research Institute, Minato-ku, Tokyo, Japan
Hiroaki Saito
6Department of Gastroenterology, Sendai Kosei Hospital, Sendai City, Miyagi, Japan
MD, PhDToyoaki Sawano
7Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan
MD, PhDErika Yamashita
2Medical Governance Research Institute, Minato-ku, Tokyo, Japan
Tetsuya Tanimoto
8Department of Internal Medicine, Navitas Clinic, Tachikawa City, Tokyo, Japan
MDAkihiko Ozaki
9Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan
MD, PhD
Article usage
Posted January 18, 2022.
Pharmaceutical Payments to Japanese Certificated Hematologists: A Retrospective Analysis of Personal Payments from Pharmaceutical Companies between 2016 and 2019
Eiji Kusumi, Anju Murayama, Sae Kamamoto, Moe Kawashima, Makoto Yoshida, Hiroaki Saito, Toyoaki Sawano, Erika Yamashita, Tetsuya Tanimoto, Akihiko Ozaki
medRxiv 2022.01.17.22269284; doi: https://doi.org/10.1101/2022.01.17.22269284
Pharmaceutical Payments to Japanese Certificated Hematologists: A Retrospective Analysis of Personal Payments from Pharmaceutical Companies between 2016 and 2019
Eiji Kusumi, Anju Murayama, Sae Kamamoto, Moe Kawashima, Makoto Yoshida, Hiroaki Saito, Toyoaki Sawano, Erika Yamashita, Tetsuya Tanimoto, Akihiko Ozaki
medRxiv 2022.01.17.22269284; doi: https://doi.org/10.1101/2022.01.17.22269284
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)